CD274 and nasopharyngeal carcinoma: A recent trial of famitinib and camrelizumab (PD-1 ICI) was conducted in 18 patients with R/M nasopharyngeal carcinoma who had already progressed on one line of platinum-based chemotherapy and anti-PD-L1 immunotherapy.